{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T19:12:17Z","timestamp":1769195537442,"version":"3.49.0"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.msard.2017.09.029","type":"journal-article","created":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T14:45:11Z","timestamp":1506350711000},"page":"170-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["\u201cNail loss after teriflunomide treatment: A new potential adverse event\u201d"],"prefix":"10.1016","volume":"18","author":[{"given":"L.","family":"Mancinelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Amerio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"di Ioia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Di Tommaso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Onofrj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lugaresi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2017.09.029_bib1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1540-9740.2005.02366.x","article-title":"Hair and nail relationship","volume":"4","author":"Baran","year":"2005","journal-title":"Skinmed"},{"issue":"6","key":"10.1016\/j.msard.2017.09.029_bib2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40265-014-0212-x","article-title":"Teriflunomide and its mechanism of action in multiple sclerosis","volume":"74","author":"Bar-Or","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.msard.2017.09.029_bib3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.msard.2015.11.006","article-title":"Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions","volume":"5","author":"Comi","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"8\u20139","key":"10.1016\/j.msard.2017.09.029_bib4","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1081\/NCN-200027547","article-title":"Dihydroorotate dehydrogenase mRNA and protein expression analysis in normal and drug-resistant cells","volume":"23","author":"L\u00f6effler","year":"2004","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"1\u20132","key":"10.1016\/j.msard.2017.09.029_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000446118","article-title":"Proposing a simpler classification of telogen effluvium","volume":"2","author":"Rebora","year":"2016","journal-title":"Skin. Appendage\u00a0Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034817302407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034817302407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:41:10Z","timestamp":1761900070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034817302407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":5,"alternative-id":["S2211034817302407"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2017.09.029","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cNail loss after teriflunomide treatment: A new potential adverse event\u201d","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2017.09.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}